Long-term clinical outcomes of patients receiving proton beam therapy for caudate lobe hepatocellular carcinoma
| Autor: | Toshiki Ishida, Shosei Shimizu, Toshiyuki Okumura, Takashi Saito, Masatoshi Nakamura, Kei Nakai, Hiroaki Takahashi, Yu-Lun Tsai, Haruko Numajiri, Yuichi Hiroshima, Daichi Takizawa, Yuta Sekino, Takashi Iizumi, Hideyuki Sakurai, Masashi Mizumoto |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Multivariate analysis Carcinoma Hepatocellular Health Toxicology and Mutagenesis medicine.medical_treatment Radiation Dosage Gastroenterology Disease-Free Survival 030218 nuclear medicine & medical imaging Oncology/Medicine 03 medical and health sciences hepatocellular carcinoma (HCC) 0302 clinical medicine Internal medicine medicine Overall survival Proton Therapy Caudate lobe Humans Radiology Nuclear Medicine and imaging In patient Adverse effect radiotherapy Aged Aged 80 and over Radiation business.industry Liver Neoplasms caudate lobe proton beam therapy (PBT) Dose-Response Relationship Radiation Middle Aged medicine.disease digestive system diseases Radiation therapy Single tumour Treatment Outcome 030220 oncology & carcinogenesis Hepatocellular carcinoma Multivariate Analysis AcademicSubjects/SCI00960 Female AcademicSubjects/MED00870 business |
| Zdroj: | Journal of Radiation Research |
| ISSN: | 1349-9157 0449-3060 |
| Popis: | Hepatocellular carcinoma (HCC) located in the caudate lobe (caudate HCC) is rare; however, patients with this type of tumour have poorer prognoses than those with HCC in other segments. Despite many published reports on the clinical usefulness of proton beam therapy (PBT) for HCC, data on the clinical outcomes of patients undergoing PBT for caudate HCC remain scarce. Therefore, the present study aimed to investigate the outcomes of this group of patients. Thirty patients with caudate HCC who underwent definitive PBT between February 2002 and February 2014 were retrospectively analysed. The total irradiation doses ranged from 55 to 77 (median 72.6) Gy relative biological dose. The median follow-up period was 37.5 (range, 3.0–152.0) months. The overall survival (OS) rates at one, three and five years were 86.6%, 62.8% and 46.1%, respectively. According to univariate and multivariate analyses, Child-Pugh A (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|